

The state of menopause clinical trials, Q4 2026

A snapshot of every menopause, perimenopause, hot-flush and genitourinary-syndrome trial that is open or about to open, from the US registry (ClinicalTrials.gov) and the EU registry (CTIS).

Data pulled 21 October 2026, 13:27 Irish time (UTC+1)

Sources: ClinicalTrials.gov API v2 + EU CTIS

281

open or not-yet-recruiting trials

14

at Phase 3 or Phase 2/3

14%

led by industry (39 trials)

6

testing NK3 / NK1,3 antagonists

107

ongoing US-registry studies due to finish in the next 12 months

Headline findings

1. **281 menopause trials are open or about to open** across the two registries (273 on ClinicalTrials.gov, 8 in the EU's CTIS). 61 of them are observational studies that test no treatment.
2. **Late-stage drug trials are rare.** Only 14 open trials are at Phase 3 or Phase 2/3, against 167 interventional trials with no drug phase (behavioural, supplement, device and similar studies).
3. **Most menopause research is academic.** Industry is the lead sponsor of 39 open trials (14%), spread across 34 companies. Only 7 of those 39 industry trials carry a drug-

development phase; the rest test supplements, consumer products, devices or apps, or are observational.

4. **The new non-hormonal drugs are a small slice so far.** 6 open interventional trials test an NK3 or NK1,3 antagonist (fezolinetant or elinzanetant), compared with 36 testing hormonal therapy, 79 behavioural or lifestyle approaches and 53 supplements.


5. **The US leads, Europe follows, Ireland barely features.** Of the 242 open trials that list sites, 86 (36%) recruit in the US and 67 (28%) in the EU; 1 lists an Irish site.

Download: [PDF version](#) [The 281 open trials \(CSV\)](#) [All figures \(JSON\)](#)

1. Phase: mostly non-drug studies

Of the 220 open interventional trials, 167 have no drug phase. These test behaviour change, exercise, supplements, devices and similar approaches. 53 carry a drug-development phase, and 14 of those are at Phase 3 or Phase 2/3.

Open interventional menopause trials by phase (n=220)




Source: TrialsForHer analysis of ClinicalTrials.gov and EU CTIS, data pulled 21 October 2026

2. Country: the US leads, Europe follows, Ireland barely features

242 of the 281 open trials list at least one site. 86 recruit in the United States, 67 in at least one EU country and 13 in the United Kingdom. 76 recruit only outside the US, UK and EU. The most active EU countries are Spain (16), Italy (9), France (8), Denmark (7), Sweden (5), Germany (4).

Ireland. 1 open menopause trial lists a site in Ireland: [NCT07417228](#) (The Impact of Concurrent Training on Women Experiencing Symptoms of Menopause, sponsor: University College Dublin). Across all 1,460 menopause records in both registries (any status, any year), 6 have ever listed an Irish site.



3. Sponsors: academic-led, with a long tail of companies

Universities, hospitals and other non-profits lead most open trials. Industry leads 39 (14%), spread across 34 companies; 29 of those companies have just one open trial. Companies with more than one open trial:


COMPANY (LEAD SPONSOR)	OPEN TRIALS
Bayer	2
Stratpharma AG	2
SRI International	2
Astellas	2
Mucosa Innovations, S.L.	2

Industry-led open trials with a drug-development phase:

TRIAL	COMPANY	PHASE	TITLE
NCT07829653	Astellas Pharma Inc	Phase 3	A Study to Confirm if Fezolinetant Helps to Reduce Hot Flashes in Indian Women Going Through Menopause
NCT07794150	Corium Innovations, Inc.	Phase 1	A Study to Assess the Skin Irritation and Sensitization of Estradiol/Levonorgestrel TDS in Healthy Postmenopausal Subjects
NCT07762287	Bayer	Phase 1	Evaluation of Possible Ways the Body May Process Two Different Forms of Elinzanetant in Healthy Study Participants
NCT06644573	Nyree Penn	Phase 1	Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia
NCT07042516	Tioga Pharmaceuticals	Phase 2	Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS).
NCT07850050	Boehringer Ingelheim	Phase 3	SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight
2024-520234-30-00	The Pharmaceutical Company LEK-AM Sp. Zoo., Przedsiębiorstwo Farmaceutyczne Lek-Am Sp. z o.o.	Phase 3	A randomized, double-blind, placebo-controlled, multicenter study evaluating the effect of a 12-week DHEA combination of 20 mg and 2 mg prolonged-release melatonin on sleep quality and mood in postmenopausal women.

For context, the industry sponsors with the most menopause records of any status on ClinicalTrials.gov are Bayer (34), Novo Nordisk A/S (16), Pfizer (13), Wyeth is now a wholly owned subsidiary of Pfizer (13), Hoffmann-La Roche (9), Warner Chilcott (8), Astellas Pharma Global Development, Inc. (8), Bonafide Health (7). Sponsor names are as registered; we group only obvious variants of one company name (for example two Astellas entities).

Who sponsors open menopause trials (n=281)



Source: TrialsForHer analysis of ClinicalTrials.gov and EU CTIS, data pulled 21 October 2026

4. What is being tested


Each open trial is tagged by the treatments in its registry record, and a trial testing two kinds of treatment counts in both. Behavioural and lifestyle approaches (79) and supplements or herbal products (53) lead. Hormonal therapy appears in 36 open trials, and devices, apps and procedures in 33.

NK3 and NK1,3 antagonists are the first new class of non-hormonal drug for hot flushes. 6 open interventional trials test one:

TRIAL	LEAD SPONSOR	PHASE	TITLE
NCT07606664	Rebecca Thurston	Phase 3	Fezolinetant and Vascular Health and Brain Health
NCT06975111	University of Colorado, Denver	Phase 2/3	Focusing on the Menopausal Transition to Improve Mid-Life Women's Health
NCT06917313	Yale University	Phase 2	FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy
NCT07077395	Massachusetts General Hospital	Phase 2	Finding Links Between Hot FLASHes and CardioVascular Disease
NCT07829653	Astellas Pharma Inc	Phase 3	A Study to Confirm if Fezolinetant Helps to Reduce Hot Flashes in Indian Women Going Through Menopause
NCT07762287	Bayer	Phase 1	Evaluation of Possible Ways the Body May Process Two Different Forms of Elinzanetant in Healthy Study Participants

1 further open observational studies follow women already prescribed one of these drugs ([NCT07602530](#), Astellas Pharma Europe Ltd.).

What open interventional menopause trials test (n=220)



Source: TrialsForHer analysis of ClinicalTrials.gov and EU CTIS, data pulled 21 October 2026

5. Due to finish in the next 12 months

107 ongoing ClinicalTrials.gov studies (85 interventional) give an estimated primary completion date between 2026-10-21 and 2027-10-21; 18 are industry-led. These dates are sponsors' own estimates and often slip: 122 ongoing studies already list a primary completion date that has passed. The industry-led and Phase 2 or Phase 3 trials in that window:

TRIAL	TITLE	LEAD SPONSOR	PHASE	STATUS	PRIMARY COMPLETION (EST.)
NCT07342400	A Clinical Study to Assess Histological Changes From Treatment of Poly L-lactic Acid Biostimulator on Women at Various Menopausal Stages	Galderma R&D industry	N/A (non-drug)	Recruiting	2026-11
NCT07653620	Hydration & Female Life Stages	PepsiCo Global R&D	N/A (non-	Recruiting	2026-11

TRIAL	TITLE	LEAD SPONSOR	PHASE	STATUS	PRIMARY COMPLETION (EST.)
		industry	drug)		
NCT07393672	Effects of Hemp-Derived Cannabinoids on Menopause Symptoms	Washington State University	Phase 2	Recruiting	2026-11-10
NCT07861295	Satavari and Ashoka for Menopause (SAM) Study	Vidya USA Corporation industry	N/A (non-drug)	Recruiting	2026-12-01
NCT07611305	ProGo Menopause Wellbeing Study	Hofseth Biocare ASA industry	N/A (non-drug)	Not yet recruiting	2026-12
NCT06962345	Changes in the Impact of Genitourinary Syndrome of Menopause With a Novel Nonhormonal Vulvovaginal Gel Assessed by PROMs.	Mucosa Innovations, S.L. industry	N/A (non-drug)	Recruiting	2026-12
NCT07413705	BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and Postmenopausal Women	BTL Industries Ltd. industry	N/A (non-drug)	Recruiting	2026-12-11
NCT06111209	The Anabolic Effect of Testosterone on Pelvic Floor Muscles	Brigham and Women's Hospital	Phase 2	Active, not recruiting	2026-12-31
NCT06611514	Effect of Intravaginal Prasterone on Symptoms of Genitourinary Syndrome of Menopause (GSM) in Women in Menopause With Previous Breast Cancer	European Institute of Oncology	Phase 3	Not yet recruiting	2027-01-01
NCT07880041	Evaluation of the Effect of a Nutraceutical Supplement on Hair Growth and Hair Quality in Premenopausal and Menopausal Women	LycoRed Ltd. industry	N/A (non-drug)	Recruiting	2027-01
NCT07538167	Food Trial Evaluating Fecal Abundance of SBD111 With Once-Daily Versus Twice-Daily Administration in Healthy Adults	Solarea Bio, Inc industry	N/A (non-drug)	Not yet recruiting	2027-01

TRIAL	TITLE	LEAD SPONSOR	PHASE	STATUS	PRIMARY COMPLETION (EST.)
NCT03916978	Autologous PRP Intra Ovarian Infusion to Restore Ovarian Function in Menopausal Women	Genesis Athens Clinic	Phase 2/3	Recruiting	2027-01-30
NCT04031456	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients	Genesis Athens Clinic	Phase 2/3	Recruiting	2027-01-30
NCT05664477	PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition	Roberta Brinton	Phase 2	Active, not recruiting	2027-01-31
NCT07118891	Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause	AbCellera Biologics Inc. industry	Phase 1/2	Active, not recruiting	2027-02
NCT07762287	Evaluation of Possible Ways the Body May Process Two Different Forms of Elinzanetant in Healthy Study Participants	Bayer industry	Phase 1	Recruiting	2027-02-22
NCT07386249	Exploration of the Effect of a Wheat Polar Lipid Complex on Vaginal Dryness in Healthy Postmenopausal Women	Seppic industry	N/A (non-drug)	Recruiting	2027-03
NCT06530459	The MUSE Study for Menopausal Arthralgia	National University Hospital, Singapore	Phase 2/3	Recruiting	2027-04
NCT07548307	Radicle Revive™: A Study Assessing the Impact of Health and Wellness Products on Menopausal-Related Health Issues Associated Health Outcomes and Related Health Outcomes	Radicle Science industry	N/A (non-drug)	Active, not recruiting	2027-04-07
NCT07663305	Evaluation of a Mobile Menopause Application	Endo Health GmbH industry	N/A (non-drug)	Recruiting	2027-05
NCT07794150	A Study to Assess the Skin Irritation and Sensitization of	Corium Innovations, Inc. industry	Phase 1	Recruiting	2027-05-31

TRIAL	TITLE	LEAD SPONSOR	PHASE	STATUS	PRIMARY COMPLETION (EST.)
	Estradiol/Levonorgestrel TDS in Healthy Postmenopausal Subjects				
NCT01530373	Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients	University of Arkansas	Phase 2	Recruiting	2027-07
NCT07834463	Randomized Evaluation of Natural Extract for Menopausal Wellness (RENEW)	India Glycols Ltd industry	N/A (non-drug)	Recruiting	2027-08-31
NCT07824648	Thermoregulatory Physiology of Menopausal Hot Flashes	SRI International industry	N/A (non-drug)	Recruiting	2027-09-15

Methods

Data pulled: 21 October 2026, 13:27 Irish time (UTC+1). This report is a fixed snapshot; the [live menopause tracker](#) is refreshed weekly, so its numbers will move.

- **ClinicalTrials.gov** (API v2, clinicaltrials.gov/api/v2/studies): condition search menopause OR perimenopause OR "vasomotor symptoms" OR "hot flashes" OR "hot flashes".
- **EU CTIS** (public search at euclinicaltrials.eu): free-text and medical-condition searches for menopause, perimenopause, vasomotor symptoms, hot flushes and hot flashes, de-duplicated by EU CT number. CTIS holds trials under the EU Clinical Trials Regulation; older EU trials in EudraCT are not included.
- **Relevance filter** (the same as the live tracker): a record is kept only if its conditions or title mention menopause or perimenopause, menopausal symptoms, climacteric, vasomotor symptoms, hot flushes or night sweats, or vaginal atrophy / genitourinary syndrome of menopause. Mentions of "postmenopausal" or "premenopausal" alone do not count, and male-only trials are removed (729 records removed). For this report we also removed 7 records the filter wrongly kept (fertility trials of "human menopausal gonadotropin" and one coronary "vasomotor" trial). That leaves 1,442 ClinicalTrials.gov and 18 CTIS records.
- **Open** means "Recruiting" or "Not yet recruiting" on ClinicalTrials.gov, and "Authorised, recruitment pending", "Authorised, recruiting" or "Ongoing, recruiting" in CTIS. Some trials are registered in both registries and may be counted twice.
- **Sponsor type** uses each registry's own lead-sponsor class (ClinicalTrials.gov: industry, NIH, other federal or government, network, other; CTIS: sponsor type). "Academic, hospital & non-profit" is ClinicalTrials.gov's "other" class plus CTIS hospitals, universities and patient organisations.
- **Treatment types** are assigned by keyword rules on the intervention names and types in each record (CTIS: product names and title). Hormonal therapy covers oestrogens, progestogens, testosterone, DHEA/prasterone, tibolone and conjugated oestrogens/bazedoxifene. "Other drugs" includes non-

hormonal medicines such as SSRIs/SNRIs, oxybutynin and clonidine, and drugs used as research tools. Placebo, sham and usual-care arms are ignored. The rules are approximate; the CSV lists every trial with its tags so they can be checked.

- **Countries** are the site countries listed in each record; 39 open trials list no sites yet. EU means the 27 member states.
- **Completion dates** are the primary completion dates on ClinicalTrials.gov, usually sponsors' estimates. The CTIS public search does not give a completion date, so EU-only trials are not in section 5.

Registry records are written by trial sponsors and may be out of date. This report is information, not medical advice. If you are thinking about joining a trial, talk to your doctor and the study team.

Corrections: support@trialsforher.com.